{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:43Z","timestamp":1791645883950,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2016.11.002","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T19:31:49Z","timestamp":1481139109000},"page":"118-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment"],"prefix":"10.1016","volume":"30","author":[{"given":"Marianna","family":"Sassone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#","article-title":"Occurrence and prognosis of extranodal lymphomas","volume":"29","author":"Freeman","year":"1972","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0360-3016(03)00767-3","article-title":"Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes","volume":"57","author":"Fung","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/eop.11.16","article-title":"Descriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin's lymphoma","volume":"6","author":"Moslehi","year":"2011","journal-title":"Expert Rev Ophtalmol"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0161-6420(01)00547-4","article-title":"Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma","volume":"108","author":"Shields","year":"2001","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/bjo.84.8.907","article-title":"Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival","volume":"84","author":"Jenkins","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"5\u20136","key":"10.1016\/j.beha.2016.11.002_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/10428199909058411","article-title":"Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma","volume":"32","author":"Nakata","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.10332","article-title":"Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients","volume":"73","author":"Cho","year":"2003","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/IOP.0b013e31821cc4bb","article-title":"Primary, unilateral ocular adnexal lymphoma: disease progression and long-term survival","volume":"27","author":"Rootman","year":"2011","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"13","key":"10.1016\/j.beha.2016.11.002_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnci\/djj248","article-title":"Rapidly increasing incidence of ocular non-hodgkin lymphoma","volume":"98","author":"Moslehi","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/oem.52.6.374","article-title":"Chronic lymphocytic leukaemias and non-Hodgkin\u2019s lymphomas by histological type in farming-animal breeding workers: a population case-control study based on job titles","volume":"52","author":"Amadori","year":"1995","journal-title":"Occup Environ Med"},{"issue":"10","key":"10.1016\/j.beha.2016.11.002_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/oem.2005.021550","article-title":"Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public","volume":"62","author":"Svec","year":"2005","journal-title":"Occup Environ Med"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016331128897","article-title":"Animal-related occupations and the risk of leukemia, myeloma, and non-Hodgkin\u2019s lymphoma in Canada","volume":"13","author":"Fritschi","year":"2002","journal-title":"Cancer Causes Control"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bjc.2012.2","article-title":"Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae","volume":"106","author":"Dolcetti","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"OAML: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","author":"Ferreri","year":"2008","journal-title":"Ann Onc"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1054\/bjoc.2000.1308","article-title":"Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma","volume":"83","author":"Raderer","year":"2000","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/ICU.0b013e328010948d","article-title":"Lymphomas involving the eye and the ocular adnexa","volume":"17","author":"Coupland","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"issue":"7","key":"10.1016\/j.beha.2016.11.002_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/modpathol.3880366","article-title":"Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia","volume":"14","author":"Mannami","year":"2001","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beha.2016.11.002_bib18","first-page":"555","article-title":"Immunoglobulin VH gene expression among extranodal marginal zone B cell lymphomas of the ocular adnexa","volume":"40","author":"Coupland","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.beha.2016.11.002_bib19","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/sj.leu.2403501","article-title":"Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites","volume":"18","author":"Streubel","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrc1409","article-title":"MALT lymphoma: from morphology to molecules","volume":"4","author":"Isaacson","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib21","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","author":"Streubel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.11.002_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-1827.2004.01580.x","article-title":"No evidence of a correlation between BCL10 expression and API2- MALT1 gene rearrangement in ocular adnexal MALT lymphoma","volume":"54","author":"Adachi","year":"2004","journal-title":"Pathol Int"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1471-2407-6-249","article-title":"Fluorescence in situ hybridization (FISH) analysis of primary OAML","volume":"20","author":"Tanimoto","year":"2006","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.beha.2016.11.002_bib24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3324\/haematol.2011.040402","article-title":"Genomic profiles of MALT lymphomas: variability across anatomical sites","volume":"96","author":"Kwee","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI27476","article-title":"Delving deeper into MALT lymphoma biology","volume":"116","author":"Bertoni","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.beha.2016.11.002_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/modpathol.2016.79","article-title":"Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies","volume":"29","author":"Cani","year":"2016","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V27.4.435.435","article-title":"Autoimmune disease in NZB-bl mice. II. Autoimmunity and malignant lymphoma","volume":"27","author":"Mellors","year":"1966","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib28","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium","volume":"111","author":"Ekstrom Smedby","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2016.11.002_bib29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/aje\/kwi341","article-title":"Immune-related conditions and immune-modulating medications as risk factors for non-hodgkin's lymphoma: a case-control study","volume":"162","author":"Engels","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib30","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1172\/JCI3234","article-title":"Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. the salivary glands of patients with sjogren's syndrome","volume":"102","author":"Stott","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"1 Suppl 1","key":"10.1016\/j.beha.2016.11.002_bib31","first-page":"S94","article-title":"Lymphoid proliferations of the salivary glands","volume":"111","author":"Harris","year":"1999","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.beha.2016.11.002_bib32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.eye.6702027","article-title":"Thyroid orbitopathy possibly predisposes to late onset of periocular lymphoma","volume":"20","author":"Nutting","year":"2006","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib34","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2404782","article-title":"MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course","volume":"21","author":"W\u00f6hrer","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.1984","article-title":"Chlamydia psittaci is variably associated with OAML in different geographical regions","volume":"209","author":"Chanudet","year":"2006","journal-title":"J\u00a0Pathol"},{"issue":"11","key":"10.1016\/j.beha.2016.11.002_bib36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nrclinonc.2009.147","article-title":"Chlamydial infection: the link with ocular adnexal lymphoma","volume":"6","author":"Ferreri","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2016.11.002_bib37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nrmicro1007","article-title":"Chlamydia and apoptosis: life and death decisions of an intracellular pathogen","volume":"2","author":"Byrne","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.beha.2016.11.002_bib39","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1158\/1078-0432.CCR-08-0676","article-title":"Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods","volume":"14","author":"Ponzoni","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ijc.23596","article-title":"Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single center prospective case\u2013control study","volume":"123","author":"Ferreri","year":"2008","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib41","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/leu.2011.276","article-title":"Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation","volume":"26","author":"Dagklis","year":"2012","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.beha.2016.11.002_bib42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.12.13.1255","article-title":"Molecular mimicry and immune-mediated diseases","volume":"12","author":"Oldstone","year":"1998","journal-title":"FASEB J"},{"issue":"22","key":"10.1016\/j.beha.2016.11.002_bib43","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1200\/JCO.2005.07.083","article-title":"Regression of ocular adnexal lymphoma after chlamydia psittaci\u2013 eradicating antibiotic therapy","volume":"23","author":"Ferreri","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2016.11.002_bib44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djj373","article-title":"Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial","volume":"98","author":"Ferreri","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.beha.2016.11.002_bib45","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00277-014-2240-8","article-title":"Long term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B lymphoma","volume":"94","author":"Han","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3201\/eid0204.960406","article-title":"Chlamydiae as pathogens: new species and new issues","volume":"2","author":"Peeling","year":"1996","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib48","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1086\/516373","article-title":"Chronic follicular conjunctivitis associated with Chlamydia psittaci or Chlamydia pneumoniae","volume":"26","author":"Lietman","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ophtha.2006.09.020","article-title":"Role of Helicobacter pylori in conjunctival mucosa-associated lymphoid tissue lymphoma","volume":"114","author":"Sjo","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib51","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/bjo.2007.132316","article-title":"The association between conjunctival MALT lymphoma and Helicobacter pylori","volume":"92","author":"Lee","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.beha.2016.11.002_bib52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.leukres.2006.12.005","article-title":"Chlamydia psittaci, Helicobacter pylori and ocular adnexal lymphoma-is there an association? The German experience","volume":"31","author":"Goebel","year":"2007","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib53","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bjo.2007.134965","article-title":"Ocular adnexal lymphoma. What is the evidence for an infectious aetiology?","volume":"92","author":"Cohen","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib54","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdl027","article-title":"Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa","volume":"17","author":"Ferreri","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/annonc\/mdl369","article-title":"Hepatitis C virus infection and MALT-type ocular adnexal lymphoma","volume":"18","author":"Arnaud","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib56","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/02841860701630283","article-title":"Assessment of the role of hepatitis C, Helicobacter pylori and autoimmunity in MALT lymphoma of the ocular adnexa in 45 Austrian patients","volume":"47","author":"Gruenberger","year":"2008","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Arcaini","year":"2007","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.beha.2016.11.002_bib58","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience","volume":"24","author":"Raderer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib59","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.ophtha.2003.09.049","article-title":"Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma","volume":"111","author":"Matsuo","year":"2004","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib60","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0360-3016(02)04159-7","article-title":"Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy","volume":"55","author":"Martinet","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdj025","article-title":"Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma","volume":"17","author":"Tanimoto","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2004.03.039","article-title":"Orbital lymphoma: is it necessary to treat the entire orbit?","volume":"60","author":"Pfeffer","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1667\/RR1688.1","article-title":"Radiation cataractogenesis: a review of recent studies","volume":"172","author":"Ainsbury","year":"2009","journal-title":"Radiat Res"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/08820530500351728","article-title":"Radiotherapy and cataract formation","volume":"21","author":"Ferrufino-Ponce","year":"2006","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"International lymphoma radiation oncology group. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib66","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2011.12.097","article-title":"Risk of radiation retinopathy in patients with orbital and ocular lymphoma","volume":"84","author":"Kaushik","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"10.1016\/j.beha.2016.11.002_bib67","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","article-title":"Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome","volume":"21","author":"Tsang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0167-8140(00)00328-5","article-title":"Orbital lymphoma: radiotherapy outcome and complications","volume":"59","author":"Stafford","year":"2001","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21330","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associate lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2005.11.005","article-title":"Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy","volume":"78","author":"Ejima","year":"2006","journal-title":"Radiother Oncol"},{"issue":"1A","key":"10.1016\/j.beha.2016.11.002_bib71","first-page":"133","article-title":"Roxithromycin inhibits angiogenesis of human hepatoma cells in\u00a0vivo by suppressing VEGF production","volume":"25","author":"Aoki","year":"2005","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib72","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/47.6.867","article-title":"The effect of azithromycin and clarithromycin on ex\u00a0vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages","volume":"47","author":"Kurdowska","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3835(98)00110-4","article-title":"Inhibition of tumor angiogenesis by roxithromycin, a 14- membered ring macrolide antibiotic","volume":"131","author":"Yatsunami","year":"1998","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000007256","article-title":"Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer","volume":"46","author":"Hamada","year":"2000","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib75","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","article-title":"Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial","volume":"150","author":"Govi","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib76","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/annonc\/mdv214","article-title":"High-dose clarithromycin is a feasible and active monotherapy for patients with relapsed\/refractory extranodal marginal zone lymphoma [EMZL]: results from the \u201cHD-K\u201d phase II trial","volume":"26","author":"Ferreri","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib77","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/sonc.2003.50044","article-title":"Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone","volume":"30","author":"Coleman","year":"2003","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib78","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment- naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib79","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib80","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190701457949","article-title":"Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma","volume":"48","author":"Lossos","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.beha.2016.11.002_bib81","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid,tissue-type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.11.002_bib82","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/bcj.2014.65","article-title":"Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma","volume":"4","author":"Mino","year":"2014","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib83","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/02713683.2014.959605","article-title":"Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience","volume":"40","author":"Tuncer","year":"2015","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","author":"Samaniego","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib85","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3109\/10428194.2014.975801","article-title":"Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma","volume":"56","author":"Lossos","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2078","article-title":"Efficacy of\u2079\u2070Yttrium-ibritumomab tiuxetan in relapsed\/refractory extranodal marginal-zone lymphoma","volume":"32","author":"Vanazzi","year":"2014","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2016.11.002_bib87","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","article-title":"Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma","volume":"20","author":"Esmaeli","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ophtha.2010.04.036","article-title":"Intralesional rituximab. A new therapeutic approach for patients with conjunctival lymphomas","volume":"118","author":"Ferreri","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib89","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.leukres.2011.01.030","article-title":"Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation","volume":"35","author":"Laurenti","year":"2011","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.beha.2016.11.002_bib90","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00432-013-1438-9","article-title":"Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections","volume":"139","author":"Savino","year":"2013","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2016.11.002_bib91","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/annonc\/mdp349","article-title":"Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"20","author":"Troch","year":"2009","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beha.2016.11.002_bib92","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A\u00a0phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.11.002_bib94","article-title":"A\u00a0phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)","author":"Kiesewetter","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2015-0176","article-title":"Delayed efficacy after treatment with lenalidomide or thalidomide in patients with mucosa-associated lymphoid tissue lymphoma","volume":"21","author":"Kiesewetter","year":"2016","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.beha.2016.11.002_bib96","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2016.11.002_bib97","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/annonc\/mdg492","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)","volume":"14","author":"W\u00f6hrer","year":"2003","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.beha.2016.11.002_bib98","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ophtha.2006.01.057","article-title":"Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit","volume":"113","author":"Ben Simon","year":"2006","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib99","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.beha.2016.11.002_bib100","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"J\u00e4ger","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2016.11.002_bib101","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","article-title":"Prolonged clinical remission in patients with extra- nodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 Year follow-up of a phase II trial","volume":"17","author":"J\u00e4ger","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2012.072587","article-title":"Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie","volume":"98","author":"Troch","year":"2013","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.beha.2016.11.002_bib103","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2016.11.002_bib104","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000098555","article-title":"Activity of rituximab plus cyclophosphamide, doxorubicin\/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma","volume":"70","author":"Raderer","year":"2006","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.beha.2016.11.002_bib105","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A\u00a0phase II study of bortezomib in patients with MALT lymphoma","volume":"94","author":"Troch","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2016.11.002_bib106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"International extranodal lymphoma study group. Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.11.002_bib107","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.11.002_bib108","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1102\/1470-7330.2006.0021","article-title":"Diffusion-weighted magnetic resonance imaging and its application to cancer","volume":"6","author":"Charles-Edwards","year":"2006","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.beha.2016.11.002_bib109","article-title":"Benign and malignant orbital lymphoproli ferative disorders: differentiating using multiparametric MRI at 3.0T","author":"Xu","year":"2016","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.beha.2016.11.002_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/jmri.25480","article-title":"Lymphoma and inflammation in the orbit: diagnostic performance with diffusion-weighted imaging and dynamic contrast-enhanced MRI","author":"Sun","year":"2016","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"2","key":"10.1016\/j.beha.2016.11.002_bib111","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1148\/radiol.10100086","article-title":"Ocular adnexal lymphoma: diffusion-weighted mr imaging for differential diagnosis and therapeutic monitoring","volume":"256","author":"Politi","year":"2010","journal-title":"Radiology"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616301256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616301256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T01:56:15Z","timestamp":1718934975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616301256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":111,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1521692616301256"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.11.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}